{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:49:23Z","timestamp":1786373363508,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.2215\/cjn.07460714","type":"journal-article","created":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T11:19:15Z","timestamp":1427973555000},"page":"732-739","source":"Crossref","is-referenced-by-count":60,"title":["Statins and Cardiovascular Primary Prevention in CKD"],"prefix":"10.2215","volume":"10","author":[{"given":"Rupert W.","family":"Major","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Kay","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel J.","family":"Brunskill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20230601","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-4-20230601","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease.","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-4-20230601","doi-asserted-by":"crossref","first-page":"E1189","DOI":"10.1503\/cmaj.101280","article-title":"Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis.","volume":"183","author":"Tonelli","year":"2011","journal-title":"CMAJ"},{"key":"R5-4-20230601","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis.","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"R6-4-20230601","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-157-4-201208210-00005","article-title":"Lipid-lowering therapy in persons with chronic kidney disease: A systematic review and meta-analysis.","volume":"157","author":"Upadhyay","year":"2012","journal-title":"Ann Intern Med"},{"key":"R7-4-20230601","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jacc.2012.12.034","article-title":"Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.","volume":"61","author":"Erickson","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R9-4-20230601","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial.","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"R16-4-20230601","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.ajkd.2009.09.020","article-title":"Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: A post hoc analysis of the Air Force\/Texas Coronary Atherosclerosis Prevention Study.","volume":"55","author":"Kendrick","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R17-4-20230601","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","article-title":"Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: An analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).","volume":"54","author":"Colhoun","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R18-4-20230601","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","article-title":"Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: A secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.","volume":"55","author":"Ridker","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R19-4-20230601","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.atherosclerosis.2009.03.031","article-title":"Pravastatin and cardiovascular risk in moderate chronic kidney disease.","volume":"206","author":"Nakamura","year":"2009","journal-title":"Atherosclerosis"},{"key":"R20-4-20230601","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"key":"R21-4-20230601","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease.","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"R22-4-20230601","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: The difference between two estimates.","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"R23-4-20230601","first-page":"2889","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"63","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"R24-4-20230601","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: Prospective derivation and validation of QRISK2.","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"},{"key":"R25-4-20230601","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacc.2007.03.037","article-title":"The Framingham predictive instrument in chronic kidney disease.","volume":"50","author":"Weiner","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R26-4-20230601","doi-asserted-by":"crossref","first-page":"iii73","DOI":"10.1093\/ndt\/gfs269","article-title":"Estimating the financial cost of chronic kidney disease to the NHS in England.","volume":"27","author":"Kerr","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R27-4-20230601","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-2-1","article-title":"Simpson\u2019s paradox and calculation of number needed to treat from meta-analysis.","volume":"2","author":"Cates","year":"2002","journal-title":"BMC Med Res Methodol"},{"key":"R28-4-20230601","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2288-2-2","article-title":"Pooling data for number needed to treat: No problems for apples.","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Med Res Methodol"},{"key":"R29-4-20230601","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2288-2-3","article-title":"Meta-analysis, Simpson\u2019s paradox, and the number needed to treat.","volume":"2","author":"Altman","year":"2002","journal-title":"BMC Med Res Methodol"},{"key":"R30-4-20230601","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R31-4-20230601","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R32-4-20230601","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(13)62388-0","article-title":"Statins: New American guidelines for prevention of cardiovascular disease.","volume":"382","author":"Ridker","year":"2013","journal-title":"Lancet"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201505000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:15Z","timestamp":1786369515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201505000-00004"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.07460714","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}